# Byrna Technologies Inc.: financial statements, quarterly

BYRN · Nasdaq · CIK 1354866 · [Technology](/sectors/technology.md) · fiscal year ends Nov 30

Pages: [Overview](/companies/byrn.md) · [Financials](/companies/byrn/financials.md) · [Filings](/companies/byrn/filings.md) · [Insiders](/companies/byrn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/byrn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q4 FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.6 d](/filings/0001437749-25-003081.md) | [16.7](/filings/0001437749-25-011592.md) | [20.3](/filings/0001437749-25-022479.md) | [20.9](/filings/0001437749-25-030736.md) | [28.0 d](/filings/0001437749-26-003206.md) | [26.2](/filings/0001437749-26-011820.md) | [28.5](/filings/0001437749-26-023100.md) | [28.2](/filings/0001437749-26-032353.md) | [35.2 d](/filings/0001437749-26-003206.md) | [29.0](/filings/0001437749-26-011820.md) | [16.4](/filings/0001437749-26-023100.md) | [15.3](/filings/0001437749-26-032353.md) |
| Cost of revenue | $m | [6.6 d](/filings/0001437749-25-003081.md) | [7.0](/filings/0001437749-25-011592.md) | [7.7](/filings/0001437749-25-022479.md) | [7.8](/filings/0001437749-25-030736.md) | [10.4 d](/filings/0001437749-26-003206.md) | [10.3](/filings/0001437749-26-011820.md) | [10.9](/filings/0001437749-26-023100.md) | [11.3](/filings/0001437749-26-032353.md) | [14.2 d](/filings/0001437749-26-003206.md) | [11.6](/filings/0001437749-26-011820.md) | [14.6](/filings/0001437749-26-023100.md) | [3.1](/filings/0001437749-26-032353.md) |
| Gross profit | $m | [9.0 d](/filings/0001437749-25-003081.md) | [9.6](/filings/0001437749-25-011592.md) | [12.6](/filings/0001437749-25-022479.md) | [13.0](/filings/0001437749-25-030736.md) | [17.6 d](/filings/0001437749-26-003206.md) | [15.9](/filings/0001437749-26-011820.md) | [17.6](/filings/0001437749-26-023100.md) | [16.9](/filings/0001437749-26-032353.md) | [21.1 d](/filings/0001437749-26-003206.md) | [17.4](/filings/0001437749-26-011820.md) | [1.8](/filings/0001437749-26-023100.md) | [12.2](/filings/0001437749-26-032353.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(0.9) d](/filings/0001437749-25-003081.md) | [(0.2)](/filings/0001437749-25-011592.md) | [1.9](/filings/0001437749-25-022479.md) | [0.8](/filings/0001437749-25-030736.md) | [4.1 d](/filings/0001437749-26-003206.md) | [1.7](/filings/0001437749-26-011820.md) | [3.3](/filings/0001437749-26-023100.md) | [2.9](/filings/0001437749-26-032353.md) | [4.0 d](/filings/0001437749-26-003206.md) | [0.9](/filings/0001437749-26-011820.md) | [(12.8)](/filings/0001437749-26-023100.md) | [(2.9)](/filings/0001437749-26-032353.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.3 d](/filings/0001437749-25-003081.md) | [0.0](/filings/0001437749-25-011592.md) | [0.0](/filings/0001437749-25-022479.md) | [(0.1)](/filings/0001437749-25-030736.md) | [(5.6) d](/filings/0001437749-26-003206.md) | [0.1](/filings/0001437749-26-011820.md) | [0.9](/filings/0001437749-26-023100.md) | [0.6](/filings/0001437749-26-032353.md) | [0.4 d](/filings/0001437749-26-003206.md) | [(0.0)](/filings/0001437749-26-011820.md) | [(2.7)](/filings/0001437749-26-023100.md) | [0.0](/filings/0001437749-26-032353.md) |
| Net income | $m | [(0.8) d](/filings/0001437749-25-003081.md) | [0.0](/filings/0001437749-25-011592.md) | [2.1](/filings/0001437749-25-022479.md) | [1.0](/filings/0001437749-25-030736.md) | [9.7 d](/filings/0001437749-26-003206.md) | [1.7](/filings/0001437749-26-011820.md) | [2.4](/filings/0001437749-26-023100.md) | [2.2](/filings/0001437749-26-032353.md) | [3.4 d](/filings/0001437749-26-003206.md) | [0.8](/filings/0001437749-26-011820.md) | [(10.1)](/filings/0001437749-26-023100.md) | [(2.9)](/filings/0001437749-26-032353.md) |
| Diluted EPS | $ per share | not reported | [0.00](/filings/0001437749-25-011592.md) | [0.09](/filings/0001437749-25-022479.md) | [0.04](/filings/0001437749-25-030736.md) | not reported | [0.07](/filings/0001437749-26-011820.md) | [0.10](/filings/0001437749-26-023100.md) | [0.09](/filings/0001437749-26-032353.md) | not reported | [0.03](/filings/0001437749-26-011820.md) | [(0.44)](/filings/0001437749-26-023100.md) | [(0.13)](/filings/0001437749-26-032353.md) |
| Basic EPS | $ per share | not reported | [0.00](/filings/0001437749-25-011592.md) | [0.09](/filings/0001437749-25-022479.md) | [0.05](/filings/0001437749-25-030736.md) | not reported | [0.07](/filings/0001437749-26-011820.md) | [0.11](/filings/0001437749-26-023100.md) | [0.10](/filings/0001437749-26-032353.md) | not reported | [0.04](/filings/0001437749-26-011820.md) | [(0.44)](/filings/0001437749-26-023100.md) | [(0.13)](/filings/0001437749-26-032353.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | period not labelled (2025-03-31) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [24.2](/filings/0001437749-24-011142.md) | [24.8](/filings/0001437749-24-022351.md) | [20.1](/filings/0001437749-24-031111.md) | [16.8](/filings/0001437749-26-003206.md) | [7.7](/filings/0001437749-26-011820.md) | [7.0](/filings/0001437749-25-022479.md) | not reported | [6.5](/filings/0001437749-25-030736.md) | [13.7](/filings/0001437749-26-032353.md) | [7.5](/filings/0001437749-26-011820.md) | [9.4](/filings/0001437749-26-023100.md) | [8.4](/filings/0001437749-26-032353.md) |
| Current assets | $m | [39.0](/filings/0001437749-24-011142.md) | [43.7](/filings/0001437749-24-022351.md) | [44.0](/filings/0001437749-24-031111.md) | [51.0](/filings/0001437749-26-003206.md) | [48.8](/filings/0001437749-25-011592.md) | [55.7](/filings/0001437749-25-022479.md) | not reported | [57.4](/filings/0001437749-25-030736.md) | [63.7](/filings/0001437749-26-032353.md) | [59.3](/filings/0001437749-26-011820.md) | [49.3](/filings/0001437749-26-023100.md) | [45.8](/filings/0001437749-26-032353.md) |
| Total assets | $m | [52.7](/filings/0001437749-24-011142.md) | [57.5](/filings/0001437749-24-022351.md) | [59.0](/filings/0001437749-24-031111.md) | [71.9](/filings/0001437749-26-003206.md) | [71.0](/filings/0001437749-25-011592.md) | [77.5](/filings/0001437749-25-022479.md) | not reported | [78.6](/filings/0001437749-25-030736.md) | [84.5](/filings/0001437749-26-032353.md) | [79.9](/filings/0001437749-26-011820.md) | [68.4](/filings/0001437749-26-023100.md) | [64.6](/filings/0001437749-26-032353.md) |
| Current liabilities | $m | [8.4](/filings/0001437749-24-011142.md) | [11.2](/filings/0001437749-24-022351.md) | [12.5](/filings/0001437749-24-031111.md) | [15.4](/filings/0001437749-26-003206.md) | [12.2](/filings/0001437749-25-011592.md) | [15.4](/filings/0001437749-25-022479.md) | not reported | [13.6](/filings/0001437749-25-030736.md) | [17.1](/filings/0001437749-26-032353.md) | [12.0](/filings/0001437749-26-011820.md) | [10.1](/filings/0001437749-26-023100.md) | [8.3](/filings/0001437749-26-032353.md) |
| Total liabilities | $m | [9.6](/filings/0001437749-24-011142.md) | [12.2](/filings/0001437749-24-022351.md) | [14.5](/filings/0001437749-24-031111.md) | [17.6](/filings/0001437749-26-003206.md) | [14.2](/filings/0001437749-25-011592.md) | [17.3](/filings/0001437749-25-022479.md) | not reported | [15.4](/filings/0001437749-25-030736.md) | [18.7](/filings/0001437749-26-032353.md) | [13.4](/filings/0001437749-26-011820.md) | [11.4](/filings/0001437749-26-023100.md) | [9.5](/filings/0001437749-26-032353.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [43.2](/filings/0001437749-25-011592.md) | [45.3](/filings/0001437749-25-030736.md) | [44.5](/filings/0001437749-25-030736.md) | [54.4](/filings/0001437749-26-032353.md) | [56.8](/filings/0001437749-26-023100.md) | [60.1](/filings/0001437749-25-022479.md) | [60.1](/filings/0001437749-26-032353.md) | [63.1](/filings/0001437749-26-032353.md) | [65.8](/filings/0001437749-26-032353.md) | [66.5](/filings/0001437749-26-023100.md) | [57.0](/filings/0001437749-26-032353.md) | [55.1](/filings/0001437749-26-032353.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q4 FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [7,520 d](/filings/0001437749-25-003081.md) | [3,942](/filings/0001437749-25-011592.md) | [1,933 d](/filings/0001437749-25-022479.md) | [(1,396) d](/filings/0001437749-25-030736.md) | [7,260 d](/filings/0001437749-26-003206.md) | [(3,777)](/filings/0001437749-26-011820.md) | [(5,458) d](/filings/0001437749-26-023100.md) | [(2,268) d](/filings/0001437749-26-032353.md) | [9,931 d](/filings/0001437749-26-003206.md) | [(4,424)](/filings/0001437749-26-011820.md) | [1,390 d](/filings/0001437749-26-023100.md) | [(436) d](/filings/0001437749-26-032353.md) |
| Capital expenditure | $k | [561 d](/filings/0001437749-25-003081.md) | [171](/filings/0001437749-25-011592.md) | [522 d](/filings/0001437749-25-022479.md) | [689 d](/filings/0001437749-25-030736.md) | [965 d](/filings/0001437749-26-003206.md) | [2,642](/filings/0001437749-26-011820.md) | [939 d](/filings/0001437749-26-023100.md) | [2,249 d](/filings/0001437749-26-032353.md) | [1,793 d](/filings/0001437749-26-003206.md) | [621](/filings/0001437749-26-011820.md) | [514 d](/filings/0001437749-26-023100.md) | [102 d](/filings/0001437749-26-032353.md) |
| Share repurchases | $k | [0.0 d](/filings/0001437749-25-003081.md) | not reported | not reported | [2,994 d](/filings/0001437749-25-030736.md) | [506 d](/filings/0001437749-26-003206.md) | [0.0](/filings/0001437749-26-011820.md) | [55.0 d](/filings/0001437749-26-023100.md) | [0.0 d](/filings/0001437749-26-032353.md) | [1,047 d](/filings/0001437749-26-003206.md) | [953](/filings/0001437749-26-011820.md) | [0.0 d](/filings/0001437749-26-023100.md) | [0.0 d](/filings/0001437749-26-032353.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-02-28) | Q2 FY2023 (2023-05-31) | Q3 FY2023 (2023-08-31) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [21.9](/filings/0001437749-24-011142.md) | [21.9](/filings/0001437749-24-022351.md) | [22.0](/filings/0001437749-24-031111.md) | [22.8](/filings/0001437749-25-011592.md) | [23.7](/filings/0001437749-25-022479.md) | [23.4](/filings/0001437749-25-030736.md) | [24.1](/filings/0001437749-26-011820.md) | [24.0](/filings/0001437749-26-023100.md) | [24.1](/filings/0001437749-26-032353.md) | [23.8](/filings/0001437749-26-011820.md) | [22.7](/filings/0001437749-26-023100.md) | [23.0](/filings/0001437749-26-032353.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 23,404,754 at 2026-10-08, from the cover of the [10-Q filed 2026-10-08](/filings/0001437749-26-032353.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.